[
  {
    "ts": null,
    "headline": "Vertex presents data from Phase I/II stage of trial for type 1 diabetes",
    "summary": "The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.",
    "url": "https://finnhub.io/api/news?id=8cd499a4ecea2d4198e419873fc09c760fb47fb69dec27e9d0762f0b00afb5a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750671329,
      "headline": "Vertex presents data from Phase I/II stage of trial for type 1 diabetes",
      "id": 135481880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.",
      "url": "https://finnhub.io/api/news?id=8cd499a4ecea2d4198e419873fc09c760fb47fb69dec27e9d0762f0b00afb5a2"
    }
  },
  {
    "ts": null,
    "headline": "Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea",
    "summary": "BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential bein",
    "url": "https://finnhub.io/api/news?id=0cc570843a3e91912d675ac057deb1cc45e0ee1e24d33b5353749b08cabb4631",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750665600,
      "headline": "Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea",
      "id": 135481881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential bein",
      "url": "https://finnhub.io/api/news?id=0cc570843a3e91912d675ac057deb1cc45e0ee1e24d33b5353749b08cabb4631"
    }
  }
]